Zhu Mengting, Rovella Valentina, Scimeca Manuel, Mauriello Alessandro, Shi Yufang, Bischof Julia, Woodsmith Jonathan, Anselmo Alessandro, Melino Gerry, Tisone Giuseppe, Agostini Massimiliano
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.
The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Suzhou, 215000, China.
Discov Oncol. 2024 Jan 16;15(1):10. doi: 10.1007/s12672-023-00850-9.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, occurring predominantly in patients with underlying chronic liver disease and cirrhosis. Here, we describe a case of a 62-year-old man that was admitted to our hospital and diagnosed with HCC where the cancer has already metastasized to the retroperitoneum and peritoneum. In order to better characterize the HCC, both the cancerous liver tissue and the adjacent normal liver tissue of the patient were collected and subjected to a genomic, transcriptomic and proteomic analysis. Our patient carries a highly mutated HCC, which is characterized by both somatic mutation in the following genes ALK, CDK6, TP53, PGR. In addition, we observe several molecular alterations that are associated with potential therapy resistance, for example the expression of the organic-anion-transporting polypeptide (OATP) family members B1 and B3, that mediate the transport of the anticancer drugs, has been found decreased. Overall, our molecular profiling potentially classify the patient with poor prognosis and possibly displaying resistance to pharmacological therapy.
肝细胞癌(HCC)是全球癌症相关死亡的第三大主要原因,主要发生在患有潜在慢性肝病和肝硬化的患者中。在此,我们描述了一例62岁男性患者,他被收治入我院并被诊断为HCC,癌症已转移至腹膜后和腹膜。为了更好地表征该HCC,收集了患者的癌性肝组织和相邻的正常肝组织,并进行了基因组、转录组和蛋白质组分析。我们的患者携带一种高度突变的HCC,其特征在于以下基因ALK、CDK6、TP53、PGR的体细胞突变。此外,我们观察到几种与潜在治疗耐药性相关的分子改变,例如,已发现介导抗癌药物转运的有机阴离子转运多肽(OATP)家族成员B1和B3的表达降低。总体而言,我们的分子谱分析可能将该患者归类为预后不良且可能对抗癌药物治疗耐药。